Health and Healthcare
How Novavax Is Differentiating Itself From Other Coronavirus Stocks
Published:
Last Updated:
Novavax Inc. (NASDAQ: NVAX) stock made a big step forward on Wednesday after the firm provided an update on its treatment for COVID-19. The markets got off to a bad start this week on increased selling as the result of coronavirus concerns. This stock (among others) has acted as a hedge against some of the market downturn, but this move is a definitive differentiating factor for this company in particular.
In a press release, Novavax detailed its progress in developing a novel vaccine to protect against the coronavirus. Management said that it is currently assessing multiple nanoparticle vaccine candidates in animal models prior to identifying an optimal candidate for human testing, which is expected to begin by the end of spring 2020.
Novavax created the COVID-19 vaccine candidates using its proprietary recombinant protein nanoparticle technology platform to generate antigens derived from the coronavirus spike (S) protein. Novavax expects to utilize its proprietary Matrix-M adjuvant with its COVID-19 vaccine candidate to enhance immune responses.
The company has a proven track record against previous coronavirsuses with this type of treatment, specifically with Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). In both cases, Novavax’s candidate vaccines demonstrated strong immunogenicity and 100% protection against virus challenge in preclinical testing.
Stanley C. Erck, president and CEO of Novavax, commented:
Our previous experience working with other corona viruses, including both MERS and SARS, allowed us to mobilize quickly against COVID-19 and successfully complete the critical preliminary steps to engineer viable vaccine candidates. Now that the protein has been expressed stably in our baculovirus system, we aim to identify the optimal candidate and scale up production of sufficient vaccine for preliminary clinical trials. We are now well-positioned to advance the COVID-19 vaccine candidate to Phase I clinical testing in May or June.
Novavax stock traded up about 16% on Wednesday to $9.23, in a 52-week range of $3.54 to $43.40. The consensus price target is $13.75.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
